
													
															
															Year
															DEALS // DEV.
															Country
															
															Therapeutic Area
															Study Phase
															Deal Type
															Product Type
															Dosage Form
															Lead Product
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Clodronic Acid Disodium Salt
Therapeutic Area : Musculoskeletal
Study Phase : Phase II/ Phase III
Sponsor : Pharmaceutical Development and Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Clodronate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 16, 2024
Lead Product(s) : Clodronic Acid Disodium Salt
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II/ Phase III
Sponsor : Pharmaceutical Development and Services
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Clodronic Acid Disodium Salt
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MAFTEST® adjuvant bisphosphonates therapy Bonefos, (clodronate disodium) result showed significant efficacy and reduce risk of death at 5 and 10 years by 26% and 23% respectively in early-stage (stage I-III) breast cancer patients compared with current ...
Product Name : Bonefos
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 14, 2022
Lead Product(s) : Clodronic Acid Disodium Salt
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
